Ally Bridge Group (Ny) Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$123.8M
Q ending 2026-03-31
Prior quarter
$96.0M
Q ending 2025-12-31
Change
+29.0% QoQ · +11.6% YoY
Positions
27
reported holdings
Largest positions
All 27 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Praxis Precision Medicines I | PRAX | Shares | $10.6M | 33K |
| Minerva Neurosciences Inc | NERV | Shares | $10.0M | 1.7M |
| Soleno Therapeutics Inc | SLNOEUR | Shares | $6.7M | 200K |
| Soleno Therapeutics Inc | SLNOEUR | Put | $6.7M | 200K |
| Ovid Therapeutics Inc | OVID | Shares | $6.3M | 2.8M |
| Compass Pathways Plc | CMPS | Shares | $5.8M | 1.0M |
| Tarsus Pharmaceuticals Inc | TARS | Shares | $5.7M | 81K |
| Solid Biosciences Inc | SLDB | Shares | $5.5M | 767K |
| Compass Therapeutics Inc | CMPX | Call | $5.3M | 1.0M |
| Promis Neurosciences Inc | PMN | Shares | $5.3M | 414K |
| Edgewise Therapeutics Inc | EWTX | Shares | $5.1M | 161K |
| Uniqure Nv | Call | $4.9M | 300K | |
| Eupraxia Pharmaceuticals Inc | EPRX | Shares | $4.8M | 660K |
| Cytomx Therapeutics Inc. | CTMX | Shares | $4.2M | 900K |
| Inventiva Sa | IVA | Shares | $4.1M | 745K |
| Perspective Therapeutics Inc | CATX | Shares | $3.9M | 927K |
| Abivax Sa | ABVX | Shares | $3.8M | 34K |
| Alumis Inc | ALMS | Shares | $3.7M | 167K |
| Urogen Pharma Ltd | Shares | $3.6M | 202K | |
| Capricor Therapeutics Inc | CAPR | Shares | $3.5M | 114K |
| Maze Therapeutics Inc | MAZE | Call | $3.0M | 100K |
| Whitehawk Therapeutics Inc | WHWK | Shares | $2.8M | 818K |
| Inhibikase Therapeutics Inc | IKT | Shares | $2.2M | 1.3M |
| Replimune Group Inc | REPL | Call | $1.9M | 247K |
| An2 Therapeutics Inc | ANTX | Shares | $1.8M | 526K |
| Relmada Therapeutics Inc | RLMD | Shares | $1.5M | 211K |
| Karyopharm Therapeutics Inc | KPTI | Call | $1.4M | 250K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.